A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

NCT00875979 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
DRUG: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg
DRUG: Pertuzumab 420 mg

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]